Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

What happened: Genmab ($GMAB) and Incyte ($INCY) announced a clinical trial collaboration to evaluate petosemtamab plus INCB161734 and standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer. Key numbers: Phase 1/2 study. Why it matters: Genmab said the collaboration supports its broader development strategy for petosemtamab across treatment settings and novel combinations. Incyte said the study aims to advance a new first-line treatment approach for mCRC. Market: -0.5% today ($2,640.00), +31.5% YTD — as of 07:45 UTC

Genmab ($GMAB) and Incyte ($INCY) announced a clinical trial collaboration to evaluate petosemtamab plus INCB161734 and standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer.

Genmab said the collaboration supports its broader development strategy for petosemtamab across treatment settings and novel combinations. Incyte said the study aims to advance a new first-line treatment approach for mCRC. Market: -0.5% today ($2,640.00), +31.5% YTD — as of 07:45 UTC